On the evening of October 17, Kexon Pharmaceutical announced that its partner Zhejiang Haichang Biomedical Technology Co., Ltd. recently received a marketing license approved and issued by the British Medicines and Health Products Administration to introduce the injectable paclitaxel. Injectable paclitaxel is used to treat various cancers such as metastatic breast cancer, metastatic pancreatic cancer, and non-small cell lung cancer.

On the evening of October 17, Kexon Pharmaceutical announced that its partner Zhejiang Haichang Biomedical Technology Co., Ltd. recently received a marketing license approved and issued by the British Medicines and Health Products Administration to introduce the injectable paclitaxel. Injectable paclitaxel is used to treat various cancers such as metastatic breast cancer, metastatic pancreatic cancer, and non-small cell lung cancer.